Trial reportClinical ophthalmology (Auckland, N.Z.)2022
The REVIVE Study: Long Term Outcomes of a Novel Non-Diffractive Extended Vision IOL versus Monofocal Control IOL.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Tolerance to refractive error with a new extended depth of focus intraocular lens.Eye (London, England) · 2024Trial
- Clinical Outcomes of a Non-Diffractive Extended Depth-of-Focus IOL in Eyes with Mild Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2023Trial
- Visual and Patient-Reported Outcomes of a Non-Diffractive Extended Depth-of-Focus Intraocular Lens with Micro-Monovision in Eyes with Early Macular Pathology.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Comparison of U.S. FDA premarket approval studies between two non-diffractive extended depth of focus lenses (AcrySof IQ Vivity versus TECNIS PureSee).Medical hypothesis, discovery & innovation ophthalmology journal · 2026Article
- The Science of Pseudoaccommodation and Its Therapeutic Potential.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Satisfaction and Visual Outcomes with a Non-Diffractive EDOF IOL in Post-Myopic LASIK and PRK Patients with High Corneal Spherical Aberration.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Long-Term Effectiveness of a Monofocal Intraocular Lens (IOL) Enhanced for Intermediate Vision: A 5-Year Follow-Up Study.Journal of clinical medicine · 2025Article
- Evaluation of Clareon Vivity and PureSee intraocular lenses: optical quality, depth of focus and misalignment effects.Scientific reports · 2025Article
- Assessing the clinical outcomes of a novel EDOF intraocular lens: a functional classification approach.BMC ophthalmology · 2025Article
- Evaluation of Visual Acuity, Postoperative Refractive Error, and Optical Aberrations in Patients With Previous Corneal Surgery and AcrySof IQ Vivity Intraocular Lens Implantation.Journal of ophthalmology · 2025Article
- Outcomes of a non-diffractive extended depth of focus intraocular lens in patients with well-controlled glaucoma and ocular hypertension.International journal of ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the long-term (>1 yr) outcomes a non-diffractive extended vision intraocular lens (AcrySof IQ Vivity) compared to monofocal control. Setting: This was a multicenter trial that took place in 4 separate private ophthalmology practices throughout the United States. Design: This was a prospective, non-interventional, controlled, multicenter trial. All subjects were enrolled from participants in the Food and Drug Administration (FDA) clinical trial that led to the approval of the AcrySof IQ Vivity. Methods: Binocular uncorrected distance visual acuity (UCDVA), distance corrected visual acuity (DCVA), uncorrected intermediate visual acuity (UIVA) at 66cm, distance corrected intermediate visual acuity (DCIVA) at 66cm, uncorrected near visual acuity (UNVA) at 40cm, and distance corrected near visual acuity (DCNVA) at 40cm were measured. The binocular defocus curve was measured. A 23-question survey on visual performance including questions on spectacle independence, satisfaction, dysphotopsias, and likelihood of recommending their lens to another person was used administered. Results: A total of 64 eyes of 32 subjects were enrolled. Seventeen subjects had bilateral implantation of the AcrySof IQ Vivity lens, and 15 subjects had bilateral implantation of the AcrySof IQ Monofocal (SN60WF). Mean follow up time was 1078 days for the study group compared to 1067 days for the control group (p = 0.92). There were no differences in UCVA or DCVA between the two groups. Compared to control, the AcrySof IQ Vivity group had better mean binocular UIVA (logMAR 0.29 vs 0.18; p = 0.09), DCIVA (logMAR 0.33 vs 0.11; p = 0.003), UNVA (logMAR 0.49 vs 0.30, p = 0.01), and DCNVA (logMAR 0.54 vs 0.29; p = 0.001). Conclusion: The AcrySof IQ Vivity is a novel, non-diffractive extended range of vision intraocular lens that provides long-term, enhanced visual acuity at intermediate and near ranges with high levels of patient satisfaction and minimal dysphotopsias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.